# A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

> **NCT02702141** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 44 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- DLBCL
- Diffuse Large B-cell Lymphoma
- Grade 3 Follicular Lymphoma

## Interventions

- **DRUG:** SGN-CD19B

## Key facts

- **NCT ID:** NCT02702141
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702141, "A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02702141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*